Company Profile
Immix Biopharma Stock Price, News & Catalysts
- Ticker:
- IMMX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.04 USD (-0.98%)
Close
Last updated: November 19, 2026
596M USD
Market cap
Why the stock is moving
As of Nov 19, 2026, IMMX closed down 0.98% at $7.04. No new same-company headline was identified in the current news window.
Company overview
Cell-Therapy Developer
Immix Biopharma is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for hematologic diseases. Its lead program is designed around a differentiated BCMA-targeted construct.
NXC-201 Lead Program
NXC-201 is a BCMA-directed CAR T-cell therapy with a proprietary binder, CD8 hinge, and CD3-zeta signaling architecture. Development is centered on relapsed or refractory light-chain amyloidosis, where the company is pursuing a potential registration pathway.
NEXICART-2 Study
NEXICART-2 is evaluating NXC-201 in the United States and is intended to generate the clinical dataset supporting the planned BLA. Interim data are being used to characterize response depth, durability, and safety in the target population.
Frontline Expansion
Immix also plans NEXICART-3 to evaluate NXC-201 in an earlier treatment setting. The strategy is intended to extend the program beyond heavily pretreated patients if the current clinical and regulatory path is successful.
Future catalysts
- Presentation of interim NEXICART-2 data for NXC-201 at the ASH Annual Meeting on December 14, 2026.
- Initiation of the frontline NEXICART-3 study in the first half of 2027.
- Planned BLA submission for NXC-201 in mid-2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immix Biopharma (IMMX)?
Immix Biopharma (IMMX) most recently closed at 7.04 USD, a -0.98% move versus the previous session.
What is the market cap of Immix Biopharma (IMMX)?
Immix Biopharma currently has a market capitalization of 596M USD on BioPharmSignal.
What does Immix Biopharma do?
Cell-Therapy Developer Immix Biopharma is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for hematologic diseases. Its lead program is designed around a differentiated BCMA-targeted construct. NXC-201 Lead Program NXC-201 is a BCMA-directed CAR T-cell therapy with a proprietary binder, CD8 hinge, and CD3-zeta signaling...
On which exchange is IMMX stock listed?
Immix Biopharma (IMMX) is associated with NASDAQ, United States, Biopharma.
What is NXC-201?
Presentation of interim NEXICART-2 data for NXC-201 at the ASH Annual Meeting on December 14, 2026.
Which conditions is Immix Biopharma targeting with NXC-201?
Presentation of interim NEXICART-2 data for NXC-201 at the ASH Annual Meeting on December 14, 2026.
How does Immix Biopharma describe recent progress with NXC-201?
Presentation of interim NEXICART-2 data for NXC-201 at the ASH Annual Meeting on December 14, 2026.
What is NEXICART-2?
NEXICART-2 Study NEXICART-2 is evaluating NXC-201 in the United States and is intended to generate the clinical dataset supporting the planned BLA.
